---
title: Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients
  Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and
  Sex-Matched Population
date: '2024-03-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38539420/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240328180654&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: To assess the impact of first-line treatment with targeted agents (TAs)
  or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy
  (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the
  general population, we conducted an aggregated analysis of phase 3 clinical trials,
  including the two FLAIR sub-studies, ECOG1912, and CLL13 trials. The restricted
  mean survival time (RMST), an alternative measure in outcome analyses capturing
  OS changes over ...
disable_comments: true
---
To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general population, we conducted an aggregated analysis of phase 3 clinical trials, including the two FLAIR sub-studies, ECOG1912, and CLL13 trials. The restricted mean survival time (RMST), an alternative measure in outcome analyses capturing OS changes over ...